查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867498

C-MET 和 HGF 抑制剂：全球市场份额和排名、总收入和需求预测（2025-2031 年）

C-MET & HGF Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 105 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球 c-MET 和 HGF 抑制剂市场规模估计为 34.8 亿美元，预计到 2031 年将成长至 107.13 亿美元，在 2025 年至 2031 年的预测期内，复合年增长率将达到 17.5%。

本报告对近期关税调整和国际战略反制措施对 C-MET 和 HGF 抑制剂的跨境产业布局、资本配置模式、区域经济相互依存关係和供应链重组进行了全面评估。

c-MET 和 HGF 抑制剂是一类标靶治疗，旨在抑制肝细胞生长因子 (HGF) 及其受体 c-MET 讯号通路的异常活化。此通路参与形成过程，如增殖、侵袭、血管生成和转移，特别是在肝细胞癌、肺癌、胃癌和肾癌等癌症。这些抑制剂包括小分子蛋白酪氨酸激酶抑制剂 (TKI) 和单株抗体，近年来已成为肿瘤药物研发的重点。 FDA认证核可药的卡马替尼和替泊替尼等药物因其已证实的临床疗效和安全性而加速了市场扩张。 2024 年，全球 c-MET 和 HGF 抑制剂的产量将达到约 2,400 万单位，全球平均市场价格约为每单位 145 美元。

c-MET/HGF讯号通路在多种恶性肿瘤中的异常活化或过度表现为精准肿瘤学提供了明确的标靶。辉瑞和诺华的年度报告显示，多种已通过核准的c-MET抑制剂已实现快速商业化，尤其是在晚期非小细胞肺癌（NSCLC）领域。随着全球肿瘤市场的扩张和个人化治疗通讯协定的日益普及，c-MET和HGF抑制剂在拓展适应症方面具有巨大潜力。 RNA定序等分子诊断技术的日益普及进一步加速了c-MET阳性患者的识别，并促进了治疗的推广。

儘管临床结果令人鼓舞，但c-MET和HGF抑制剂仍面临许多挑战，例如疗效差异、复杂的抗药性机制以及不利事件管理等。一些早期候选药物由于缺乏基于生物标记的标准化患者筛选方法，在III期临床试验中遭遇了令人失望的结果或挫折。在全球范围内，监管机构对可靠的真实世界安全性和有效性数据的要求日益提高，这导致研发时间和成本不断增加。

随着精准标靶治疗在临床上的应用日益广泛，C-MET抑制剂正被纳入多重药物治疗方法。根据IQVIA和FDA的数据，目前全球正在进行多项临床试验，检验C-MET抑制剂与免疫查核点抑制剂合併联合治疗。由于医疗保险政策的完善和本土生物技术公司的崛起，预计未来几年，C-MET抑制剂在中国、韩国及其他市场的渗透率将显着提升。

本报告旨在对全球 C-MET 和 HGF 抑制剂市场按地区/国家、类型和应用进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以销售量（千）和收入（百万美元）为单位，对C-MET和HGF抑制剂的市场规模、估算和预测进行了呈现，基准年为2024年，并涵盖了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定C-MET和HGF抑制剂的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

按类型分類的细分市场

  • Cabozantinib
  • Crizotinib
  • 替泊替尼
  • 其他的

应用领域

  • 医院
  • 药局

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for C-MET & HGF Inhibitors was estimated to be worth US$ 3480 million in 2024 and is forecast to a readjusted size of US$ 10713 million by 2031 with a CAGR of 17.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on C-MET & HGF Inhibitors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

C-MET & HGF inhibitors are a class of targeted therapies designed to inhibit the aberrant activation of the hepatocyte growth factor (HGF) and its receptor c-MET signaling pathway. This axis is implicated in tumorigenesis processes such as proliferation, invasion, angiogenesis, and metastasis, especially in cancers such as hepatocellular carcinoma, lung cancer, gastric cancer, and renal cancer. The inhibitors include small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. In recent years, they have become a key focus in oncology drug development. Drugs such as Capmatinib and Tepotinib, approved by the FDA, are accelerating market expansion with demonstrated clinical efficacy and safety. In 2024, global C-MET & HGF Inhibitors production reached approximately 24 million unit, with an average global market price of around US$ 145/unit.

The abnormal activation or overexpression of the c-MET/HGF signaling pathway in multiple malignancies provides a clear target for precision oncology. As revealed in annual reports from Pfizer and Novartis, several approved C-MET inhibitors have achieved rapid commercialization, especially in late-stage NSCLC. With the expanding global oncology market and increasing adoption of individualized treatment protocols, C-MET & HGF inhibitors possess significant potential for indication expansion. The growing availability of molecular diagnostics, such as RNA sequencing, further accelerates the identification of C-MET-positive patients, boosting treatment penetration.

Despite promising clinical outcomes, C-MET & HGF inhibitors face challenges including inconsistent efficacy, complex resistance mechanisms, and adverse event management. Some early candidates have underperformed in Phase III trials or faced setbacks due to the lack of standardized biomarker-based patient selection. Regulatory pressures are mounting worldwide, demanding robust real-world evidence for safety and efficacy, thus increasing development timelines and costs.

There is growing clinical acceptance of precision-targeted therapies, integrating C-MET inhibitors into multi-line treatment regimens. According to IQVIA and FDA data, numerous global clinical trials are exploring combination therapies involving C-MET inhibitors and immune checkpoint inhibitors. In China, Korea, and other markets, reimbursement policy improvements and the rise of local biotech players are expected to significantly accelerate market penetration in the coming years.

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of C-MET & HGF Inhibitors by region & country, by Type, and by Application.

The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.

Market Segmentation

By Company

  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Takeda Pharmaceutical

Segment by Type

  • Cabozantinib
  • Crizotinib
  • Tepotinib
  • Others

Segment by Application

  • Hospital
  • Drug Store

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of C-MET & HGF Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 C-MET & HGF Inhibitors Product Introduction
  • 1.2 Global C-MET & HGF Inhibitors Market Size Forecast
    • 1.2.1 Global C-MET & HGF Inhibitors Sales Value (2020-2031)
    • 1.2.2 Global C-MET & HGF Inhibitors Sales Volume (2020-2031)
    • 1.2.3 Global C-MET & HGF Inhibitors Sales Price (2020-2031)
  • 1.3 C-MET & HGF Inhibitors Market Trends & Drivers
    • 1.3.1 C-MET & HGF Inhibitors Industry Trends
    • 1.3.2 C-MET & HGF Inhibitors Market Drivers & Opportunity
    • 1.3.3 C-MET & HGF Inhibitors Market Challenges
    • 1.3.4 C-MET & HGF Inhibitors Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global C-MET & HGF Inhibitors Players Revenue Ranking (2024)
  • 2.2 Global C-MET & HGF Inhibitors Revenue by Company (2020-2025)
  • 2.3 Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024)
  • 2.4 Global C-MET & HGF Inhibitors Sales Volume by Company Players (2020-2025)
  • 2.5 Global C-MET & HGF Inhibitors Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers C-MET & HGF Inhibitors Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
  • 2.9 C-MET & HGF Inhibitors Market Competitive Analysis
    • 2.9.1 C-MET & HGF Inhibitors Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by C-MET & HGF Inhibitors Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Cabozantinib
    • 3.1.2 Crizotinib
    • 3.1.3 Tepotinib
    • 3.1.4 Others
  • 3.2 Global C-MET & HGF Inhibitors Sales Value by Type
    • 3.2.1 Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global C-MET & HGF Inhibitors Sales Value, by Type (2020-2031)
    • 3.2.3 Global C-MET & HGF Inhibitors Sales Value, by Type (%) (2020-2031)
  • 3.3 Global C-MET & HGF Inhibitors Sales Volume by Type
    • 3.3.1 Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Type (2020-2031)
    • 3.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global C-MET & HGF Inhibitors Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Drug Store
  • 4.2 Global C-MET & HGF Inhibitors Sales Value by Application
    • 4.2.1 Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global C-MET & HGF Inhibitors Sales Value, by Application (2020-2031)
    • 4.2.3 Global C-MET & HGF Inhibitors Sales Value, by Application (%) (2020-2031)
  • 4.3 Global C-MET & HGF Inhibitors Sales Volume by Application
    • 4.3.1 Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Application (2020-2031)
    • 4.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global C-MET & HGF Inhibitors Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global C-MET & HGF Inhibitors Sales Value by Region
    • 5.1.1 Global C-MET & HGF Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025)
    • 5.1.3 Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031)
    • 5.1.4 Global C-MET & HGF Inhibitors Sales Value by Region (%), (2020-2031)
  • 5.2 Global C-MET & HGF Inhibitors Sales Volume by Region
    • 5.2.1 Global C-MET & HGF Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025)
    • 5.2.3 Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031)
    • 5.2.4 Global C-MET & HGF Inhibitors Sales Volume by Region (%), (2020-2031)
  • 5.3 Global C-MET & HGF Inhibitors Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.4.2 North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.5.2 Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.6.2 Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.7.2 South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.3.2 United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.4.2 Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.5.2 China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.6.2 Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.7.2 South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.8.2 Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India C-MET & HGF Inhibitors Sales Value, 2020-2031
    • 6.9.2 India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Exelixis
    • 7.1.1 Exelixis Company Information
    • 7.1.2 Exelixis Introduction and Business Overview
    • 7.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Exelixis C-MET & HGF Inhibitors Product Offerings
    • 7.1.5 Exelixis Recent Development
  • 7.2 Ipsen
    • 7.2.1 Ipsen Company Information
    • 7.2.2 Ipsen Introduction and Business Overview
    • 7.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Ipsen C-MET & HGF Inhibitors Product Offerings
    • 7.2.5 Ipsen Recent Development
  • 7.3 Pfizer
    • 7.3.1 Pfizer Company Information
    • 7.3.2 Pfizer Introduction and Business Overview
    • 7.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Pfizer C-MET & HGF Inhibitors Product Offerings
    • 7.3.5 Pfizer Recent Development
  • 7.4 Novartis
    • 7.4.1 Novartis Company Information
    • 7.4.2 Novartis Introduction and Business Overview
    • 7.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Novartis C-MET & HGF Inhibitors Product Offerings
    • 7.4.5 Novartis Recent Development
  • 7.5 Takeda
    • 7.5.1 Takeda Company Information
    • 7.5.2 Takeda Introduction and Business Overview
    • 7.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Takeda C-MET & HGF Inhibitors Product Offerings
    • 7.5.5 Takeda Recent Development
  • 7.6 Merck KGaA
    • 7.6.1 Merck KGaA Company Information
    • 7.6.2 Merck KGaA Introduction and Business Overview
    • 7.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Merck KGaA C-MET & HGF Inhibitors Product Offerings
    • 7.6.5 Merck KGaA Recent Development
  • 7.7 Takeda Pharmaceutical
    • 7.7.1 Takeda Pharmaceutical Company Information
    • 7.7.2 Takeda Pharmaceutical Introduction and Business Overview
    • 7.7.3 Takeda Pharmaceutical C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
    • 7.7.5 Takeda Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 C-MET & HGF Inhibitors Industrial Chain
  • 8.2 C-MET & HGF Inhibitors Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 C-MET & HGF Inhibitors Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 C-MET & HGF Inhibitors Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. C-MET & HGF Inhibitors Market Trends
  • Table 2. C-MET & HGF Inhibitors Market Drivers & Opportunity
  • Table 3. C-MET & HGF Inhibitors Market Challenges
  • Table 4. C-MET & HGF Inhibitors Market Restraints
  • Table 5. Global C-MET & HGF Inhibitors Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global C-MET & HGF Inhibitors Revenue Market Share by Company (2020-2025)
  • Table 7. Global C-MET & HGF Inhibitors Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global C-MET & HGF Inhibitors Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market C-MET & HGF Inhibitors Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers C-MET & HGF Inhibitors Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
  • Table 13. Global C-MET & HGF Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global C-MET & HGF Inhibitors Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global C-MET & HGF Inhibitors Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global C-MET & HGF Inhibitors Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global C-MET & HGF Inhibitors Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global C-MET & HGF Inhibitors Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global C-MET & HGF Inhibitors Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global C-MET & HGF Inhibitors Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global C-MET & HGF Inhibitors Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global C-MET & HGF Inhibitors Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global C-MET & HGF Inhibitors Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global C-MET & HGF Inhibitors Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global C-MET & HGF Inhibitors Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global C-MET & HGF Inhibitors Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global C-MET & HGF Inhibitors Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global C-MET & HGF Inhibitors Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global C-MET & HGF Inhibitors Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global C-MET & HGF Inhibitors Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global C-MET & HGF Inhibitors Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global C-MET & HGF Inhibitors Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global C-MET & HGF Inhibitors Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global C-MET & HGF Inhibitors Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global C-MET & HGF Inhibitors Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025) & (%)
  • Table 44. Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031) & (%)
  • Table 45. Global C-MET & HGF Inhibitors Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global C-MET & HGF Inhibitors Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global C-MET & HGF Inhibitors Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions C-MET & HGF Inhibitors Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions C-MET & HGF Inhibitors Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, (2026-2031) & (K Units)
  • Table 57. Exelixis Company Information
  • Table 58. Exelixis Introduction and Business Overview
  • Table 59. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. Exelixis C-MET & HGF Inhibitors Product Offerings
  • Table 61. Exelixis Recent Development
  • Table 62. Ipsen Company Information
  • Table 63. Ipsen Introduction and Business Overview
  • Table 64. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Ipsen C-MET & HGF Inhibitors Product Offerings
  • Table 66. Ipsen Recent Development
  • Table 67. Pfizer Company Information
  • Table 68. Pfizer Introduction and Business Overview
  • Table 69. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Pfizer C-MET & HGF Inhibitors Product Offerings
  • Table 71. Pfizer Recent Development
  • Table 72. Novartis Company Information
  • Table 73. Novartis Introduction and Business Overview
  • Table 74. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Novartis C-MET & HGF Inhibitors Product Offerings
  • Table 76. Novartis Recent Development
  • Table 77. Takeda Company Information
  • Table 78. Takeda Introduction and Business Overview
  • Table 79. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. Takeda C-MET & HGF Inhibitors Product Offerings
  • Table 81. Takeda Recent Development
  • Table 82. Merck KGaA Company Information
  • Table 83. Merck KGaA Introduction and Business Overview
  • Table 84. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. Merck KGaA C-MET & HGF Inhibitors Product Offerings
  • Table 86. Merck KGaA Recent Development
  • Table 87. Takeda Pharmaceutical Company Information
  • Table 88. Takeda Pharmaceutical Introduction and Business Overview
  • Table 89. Takeda Pharmaceutical C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
  • Table 91. Takeda Pharmaceutical Recent Development
  • Table 92. Key Raw Materials Lists
  • Table 93. Raw Materials Key Suppliers Lists
  • Table 94. C-MET & HGF Inhibitors Downstream Customers
  • Table 95. C-MET & HGF Inhibitors Distributors List
  • Table 96. Research Programs/Design for This Report
  • Table 97. Key Data Information from Secondary Sources
  • Table 98. Key Data Information from Primary Sources

List of Figures

  • Figure 1. C-MET & HGF Inhibitors Product Picture
  • Figure 2. Global C-MET & HGF Inhibitors Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global C-MET & HGF Inhibitors Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global C-MET & HGF Inhibitors Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global C-MET & HGF Inhibitors Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. C-MET & HGF Inhibitors Report Years Considered
  • Figure 7. Global C-MET & HGF Inhibitors Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by C-MET & HGF Inhibitors Revenue in 2024
  • Figure 10. C-MET & HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Cabozantinib Picture
  • Figure 12. Crizotinib Picture
  • Figure 13. Tepotinib Picture
  • Figure 14. Others Picture
  • Figure 15. Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global C-MET & HGF Inhibitors Sales Value Market Share by Type, 2024 & 2031
  • Figure 17. Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 18. Global C-MET & HGF Inhibitors Sales Volume Market Share by Type, 2024 & 2031
  • Figure 19. Global C-MET & HGF Inhibitors Price by Type (2020-2031) & (US$/Unit)
  • Figure 20. Product Picture of Hospital
  • Figure 21. Product Picture of Drug Store
  • Figure 22. Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global C-MET & HGF Inhibitors Sales Value Market Share by Application, 2024 & 2031
  • Figure 24. Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 25. Global C-MET & HGF Inhibitors Sales Volume Market Share by Application, 2024 & 2031
  • Figure 26. Global C-MET & HGF Inhibitors Price by Application (2020-2031) & (US$/Unit)
  • Figure 27. North America C-MET & HGF Inhibitors Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions C-MET & HGF Inhibitors Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions C-MET & HGF Inhibitors Sales Volume (%), (2020-2031)
  • Figure 39. United States C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Europe C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 45. China C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Japan C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 51. South Korea C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Southeast Asia C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 57. India C-MET & HGF Inhibitors Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India C-MET & HGF Inhibitors Sales Value by Application (%), 2024 VS 2031
  • Figure 60. C-MET & HGF Inhibitors Industrial Chain
  • Figure 61. C-MET & HGF Inhibitors Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed